Neonatal DIC: Blood Products, FFP, Cryoprecipitate & Heparin Protocol for NICU

Disseminated Intravascular Coagulation in Neonates: A Consumptive Emergency

Disseminated intravascular coagulation (DIC) is a pathological syndrome of widespread activation of the coagulation cascade, leading to simultaneous microvascular thrombosis and consumptive coagulopathy with hemorrhage. In neonates, DIC is almost always secondary to an underlying condition, most commonly sepsis, birth asphyxia, or necrotizing enterocolitis. The neonatal coagulation system is developmentally immature, making neonates particularly vulnerable to this consumptive process. Management requires simultaneous treatment of the underlying cause and targeted replacement of consumed coagulation factors and platelets.

Pathophysiology of Neonatal DIC

The pathophysiology involves a destructive cascade:

1. Triggering event: Tissue factor exposure from sepsis, tissue injury, endothelial damage, or inflammatory cytokines
2. Coagulation activation: Massive thrombin generation causing widespread microvascular fibrin deposition
3. Consumption: Clotting factors (especially fibrinogen, Factor V, Factor VIII) and platelets are consumed faster than they can be produced
4. Secondary fibrinolysis: Plasmin activation to dissolve fibrin generates fibrin degradation products (FDPs) that further inhibit coagulation
5. Clinical result: Paradoxical simultaneous bleeding and thrombosis with end-organ damage from microvascular occlusion

Diagnosis of Neonatal DIC

Clinical Features

• Hemorrhagic manifestations: Oozing from puncture sites, petechiae, purpura, pulmonary hemorrhage, gastrointestinal bleeding, intracranial hemorrhage
• Thrombotic manifestations: Peripheral gangrene, purpura fulminans, renal cortical necrosis, hepatic failure
• General: Hemodynamic instability, shock, multiorgan dysfunction

Laboratory Diagnosis

Test	Normal Neonate (Term)	DIC Values	Significance
PT	13-20 seconds	Above 20 seconds (significantly prolonged)	Consumption of extrinsic factors
APTT	35-55 seconds	Above 70 seconds	Consumption of intrinsic factors
Fibrinogen	150-300 mg/dL	Below 100 mg/dL	Key diagnostic marker; very low suggests severe DIC
D-dimer	Below 0.5 mcg/mL	Markedly elevated	Indicates ongoing fibrinolysis
Platelet count	150,000-400,000/mcL	Below 100,000 (often below 50,000)	Consumptive thrombocytopenia
Peripheral smear	Normal RBC morphology	Schistocytes, fragmented RBCs	Microangiopathic hemolysis
FDP	Below 10 mcg/mL	Markedly elevated	Secondary fibrinolysis indicator

Important: Normal neonatal coagulation values differ significantly from adult values. PT and APTT are physiologically prolonged in neonates due to lower levels of vitamin K-dependent factors (II, VII, IX, X) and contact factors. Always use age-appropriate reference ranges. A PT above 20 seconds or APTT above 55 seconds in a term neonate warrants investigation.

Treatment Protocol: Address the Underlying Cause First

The single most important intervention in neonatal DIC is treating the underlying trigger. Blood products provide supportive care but will not resolve DIC if the triggering condition persists.

• Sepsis: Aggressive antibiotic therapy per NNF India sepsis protocol
• Birth asphyxia: Supportive care, therapeutic hypothermia if eligible
• NEC: Bowel rest, antibiotics, surgical consultation
• Hemorrhage: Source control, volume resuscitation

Blood Product Replacement Protocol

Product	Dose	Trigger	Target	Administration
Fresh Frozen Plasma (FFP)	10-15 mL/kg	PT above 20s or APTT above 70s with bleeding	Normalize PT/APTT	Over 30-60 minutes; repeat every 8-12 hours as needed
Cryoprecipitate	5-10 mL/kg	Fibrinogen below 100 mg/dL	Fibrinogen above 150 mg/dL	Over 30 minutes; each unit raises fibrinogen by approx 60-100 mg/dL
Platelet concentrate	10-15 mL/kg	Below 50,000 with bleeding; below 30,000 without bleeding	Above 50,000 (100,000 during active bleeding)	Over 30-60 minutes
Packed RBCs	10-15 mL/kg	Hb below 12 g/dL with active bleeding	Hb above 12-13 g/dL	Over 2-4 hours (or faster if acute hemorrhage)

Blood Product Ordering Priorities

1. Immediate: FFP and cryoprecipitate (restore clotting capacity first)
2. Concurrent: Platelets (if count below 50,000 with bleeding)
3. As needed: Packed RBCs for hemoglobin support
4. Reassess: Coagulation panel 30-60 minutes after each transfusion to guide further products

Heparin in Neonatal DIC: Limited and Specific Role

Heparin therapy in DIC is the most controversial aspect of management. It is NOT indicated in the majority of neonatal DIC cases, particularly those with active hemorrhage. Specific scenarios where heparin may be considered include:

Indications for Heparin

• Thrombosis-predominant DIC: Purpura fulminans with identifiable thrombi, renal vein thrombosis, extensive peripheral gangrene
• Ongoing consumption despite adequate replacement: When blood products are being consumed as fast as they are given, suggesting unchecked coagulation activation
• Prior to exchange transfusion: Low-dose heparin may be added to prevent consumption of transfused factors

Heparin Dosing for Neonatal DIC

Parameter	Specification
Initial dose	10-25 units/kg/hr continuous IV infusion (NO bolus in DIC)
Monitoring	Anti-Xa levels every 6 hours initially
Target anti-Xa	0.3-0.7 IU/mL
APTT monitoring	Unreliable in DIC; use anti-Xa levels
Duration	Until thrombotic component resolves; typically 3-7 days
Reversal agent	Protamine sulfate (1 mg per 100 units heparin given in last 2-3 hours)

Safety Warning: Never start heparin in a neonate with active hemorrhage from DIC. Heparin will worsen bleeding. Only consider heparin when thrombosis is the predominant manifestation and bleeding is controlled with blood product replacement. Always consult a pediatric hematologist when possible before initiating heparin in neonatal DIC.

Monitoring During DIC Treatment

• Coagulation panel: PT, APTT, fibrinogen, D-dimer every 6-8 hours during active DIC
• CBC with platelet count: Every 6-8 hours
• Blood gas: Monitor for acidosis (worsens coagulopathy)
• Hemodynamics: Continuous heart rate, blood pressure, SpO2
• Clinical bleeding assessment: Puncture sites, ETT aspirate, urine, stool
• Fluid balance: Account for blood product volumes in total fluid calculations
• Temperature: Maintain normothermia (hypothermia worsens coagulopathy)

Vitamin K Supplementation

All neonates with DIC should receive vitamin K if not already administered at birth:

• Term neonates: 1 mg IM (or 0.5-1 mg IV slowly)
• Preterm neonates: 0.5 mg IM (or 0.3-0.5 mg IV slowly)
• Vitamin K deficiency should be considered and corrected as a contributing factor, especially if birth dose was missed (common in out-of-hospital births in India)

Exchange Transfusion in Severe DIC

In severe, refractory DIC with massive bleeding and hemodynamic instability despite maximal blood product support, a double-volume exchange transfusion (160-200 mL/kg) using fresh whole blood or reconstituted blood (PRBC plus FFP) can be considered. This removes consumed factors, FDPs, and cytokines while replenishing fresh coagulation factors. It is a rescue measure primarily available in Level III NICUs with exchange transfusion capability.

Indian NICU Considerations

Managing DIC in Indian NICUs presents unique challenges:

• Blood product availability: Cryoprecipitate and specific platelet concentrates may not be immediately available in all blood banks; advance communication with the blood bank for high-risk cases is essential
• Coagulation testing: Some Level II SNCUs may have limited access to APTT and fibrinogen testing; PT and platelet count should be available at minimum
• Gram-negative sepsis predominance: Since gram-negative sepsis is the leading cause of neonatal DIC in India, aggressive empiric antibiotic therapy per NNF guidelines is paramount
• Hypothermia prevention: Hypothermia is common in Indian neonatal settings and significantly worsens coagulopathy; maintaining thermal chain is a critical adjunct to DIC management
• HEAMAC neonatal care resources support Indian NICUs in developing standardized DIC management protocols and blood product utilization guidelines

Prognosis and Outcomes

The prognosis of neonatal DIC depends primarily on the underlying cause and the speed of intervention:

• DIC from sepsis carries 20-40% mortality, higher with gram-negative organisms
• DIC from birth asphyxia resolves with supportive care in many cases as the triggering event is time-limited
• DIC from NEC depends on surgical vs medical management outcomes
• Long-term complications include organ damage from microvascular thrombosis, particularly renal and hepatic

Conclusion

Neonatal DIC requires a dual strategy: aggressive treatment of the underlying cause and targeted blood product replacement. FFP, cryoprecipitate, and platelets form the cornerstone of supportive therapy, while heparin is reserved for thrombosis-predominant presentations. Indian NICUs must ensure timely access to coagulation testing and blood products, maintain normothermia, and apply NNF-recommended sepsis protocols to address the most common trigger of neonatal DIC in the Indian clinical context.